Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Procyon enters cancer technology option agreement

Dec. 11, 2001

FDA lifts hold on phase III trial of Aptosyn + Taxotere

Dec. 10, 2001

Tubulin polymerization inhibitor effective against refractory tumors in clinical trials

Dec. 10, 2001

PSC-833, an MDR modulator, examined in untreated AML patients of different age groups

Dec. 10, 2001

Sugen presents in vitro data on indolinone related to SU-5416 at Hematology meeting

Dec. 10, 2001

Thioredoxin-targeting class of antitumor agents synthesized at U.K. university

Dec. 7, 2001

SU-11654 inhibits receptor tyrosine kinases, including mutant forms of Kit

Dec. 7, 2001

Phosphoramidate prodrugs enabling enhanced intracellular delivery of drugs

Dec. 7, 2001

MediGene seeks marketing authorization for Leuprogel in Germany

Dec. 7, 2001

Replicons kill human glioma cells in preclinical study

Dec. 7, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...